Tradestie Institutional Equity Comparison Engine

ICUI vs IFLO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICUI Overall Edge

ICUI Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ICU Medical Inc (ICUI) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ICUI trades at 17.8x Forward P/E with 6.7% operating margin (+4.4% YoY revenue) versus IFLO at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ICUI sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro) against IFLO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ICUI
ICUI 17.8x vs IFLO N/M Fwd P/E
Growth & Margin Winner ICUI
Op Margin 6.7% vs N/A ยท YoY +4.4% vs N/A
Momentum & Technical Winner ICUI
1Y +30.1% vs +22.0% ยท 52W Pos 74% vs 63%
Options & Structure Winner ICUI
UNCLASSIFIED (2nd %ile IV) vs UNCLASSIFIED (N/A IV)
ICUI NASDAQ
ICU Medical Inc
Surgical & Medical Instruments & Apparatus
$172.52
-1.84% 1D
Market Cap $4.4B
1M Return +2.49%
1Y Return +30.14%
Forward P/E 17.8x
Unified AI Score
49.5 / 100 HOLD
Tech 45.0 Fund 47.0 Flow 50.0 Mom 50.0
IFLO NASDAQ
VictoryShares International Free Cash Flow ETF
Institutional Equity
$33.75
-2.02% 1D
Market Cap N/A
1M Return -6.34%
1Y Return +22.0%
Forward P/E N/M
Unified AI Score
35.7 / 100 SELL
Tech 8.0 Fund 42.0 Flow 50.0 Mom 46.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICUI +30.14% IFLO +22.0% Spread: +6.46 pp (ICUI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ICUI TTM Op. Margin: 6.7% IFLO TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICUI vs IFLO. Trailing 12-month operating profitability (ICUI 6.7% vs IFLO N/A) and valuation multiples (ICUI 17.8x vs IFLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICUI (9) vs IFLO (1)
Institutional Metric ICUI IFLO Criterion Row Winner
Market Capitalization Scale $4.4B N/A Larger Scale ICUI
Trailing P/E Ratio Valuation 73.5x N/M Lower Multiple ICUI
Forward P/E Ratio Valuation 17.8x N/M Lower Multiple ICUI
Revenue Growth (YoY) Growth +4.4% N/A Higher Growth ICUI
Operating Margin (TTM) Profitability 6.7% N/A Higher Margin ICUI
Net Profit Margin Profitability 2.8% N/A Higher Margin ICUI
Return on Equity (ROE) Capital Efficiency 2.8% N/A Higher ROE ICUI
52-Week Range Position Momentum 74% ($113โ€“$193) 63% ($27โ€“$38) Stronger Trend ICUI
Beta / 30D Volatility Risk Regime 0.86ฮฒ ยท 38% Vol 0.76ฮฒ ยท 18% Vol Lower Realized Risk IFLO
Unified Institutional Score Composite Signal 49.5 / 100 (HOLD) 35.7 / 100 (SELL) Higher Composite ICUI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICUI vs IFLO Buy Guide
ICUI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 2nd %ile
IV Regime Compressed (<25th %ile)
Live ICUI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IFLO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IFLO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICUI nor IFLO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.